摘要
目的探讨口服阿法骨化醇冲击治疗维持性血液透析患者继发性甲状旁腺功能亢进（SHPT）的疗效。方法 10例维持性血液透析继发甲状旁腺功能亢进患者,在给予钙浓度为1.5 mmol/L透析液常规2-3次/周透析基础上,根据SHPT的程度给予阿法骨化醇冲击治疗,观察治疗效果。结果 1例因治疗过程中出现高钙血症退出治疗,后行肾移植;余9例治疗前后血钙、血磷水平比较差异无统计学意义（P〉0.05）,治疗后甲状旁腺激素（PTH）水平低于治疗前（P〈0.05）。结论阿法骨化醇冲击治疗能有效控制维持性血液透析患者SHPT。
Objective To investigate oral administration of alfacalcidol impact therapy for secondary hyperparathyroidism（SHPT） in maintenance hemodialysis patients.Methods A total of 10 maintenance hemodialysis patients with secondary hyperparathyroidism received additional alfacalcidol impact therapy to conventional 1.5 mmol/L of calcium dialyzate by 2~3 times/week in accordance with SHPT degree.Their curative effects were observed.Results There was 1 quit case due to hypercalcemia,who received kidney transplant.The other 9 cases had no statistically significant difference of blood calcium and phosphate before and after treatment（P〈0.05）.Their parathyroid hormone（PTH） level after treatment was higher than that before treatment（P〈0.05）.Conclusion Alfacalcidol impact therapy can effective control SHPT in maintenance hemodialysis patients.
出处
《中国实用医药》
2016年第28期28-30,共3页
China Practical Medicine
